Almirall and BioFocus enter Research Alliance
News Jan 25, 2012
Under the terms of the collaboration, BioFocus will apply its integrated drug discovery capabilities whilst Almirall will bring in respiratory specific knowhow to the joint experimental effort. The value of this collaboration to BioFocus could reach €7.5 million.
“We selected BioFocus for this alliance because of the excellent technology and scientific fit between both companies,” said Dr. Bertil Lindmark, CSO, Executive Director R&D of Almirall.
“We are delighted to form a drug discovery alliance with one of Europe’s leading research-based pharmaceutical companies,” added Dr. Chris Newton, SVP Galapagos Services and Managing Director, BioFocus.
Respiratory is a key research focus for Almirall together with gastrointestinal and dermatology areas where the company is especially engaged to offer new therapeutic solutions.
Easily Automate PK Assays for Human IgG Drugs in Preclinical SpeciesNews
At AAPS NBC event, Lumigen produced a poster summarizing the use of their pipetting robot, Andrew which can measure IgG drug concentration in a pre-clinical setting.READ MORE
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Comments | 0 ADD COMMENT
8th International Symposium on Recent Advances in Food Analysis (RAFA 2017)
Nov 07 - Nov 10, 2017
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017